| References: |
Decernotinib(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.
in vitro: VX-509 potently inhibits JAK3 in enzyme assays (Ki =2.5 nM + 0.7 nM) and cellular assays dependent on JAK3 activity (IC50 range, 50-170 nM), with limited or no measurable potency against other JAK isotypes or non-JAK kinases.
in vivo: VX-509 also showed activity in two animal models of aberrant immune function. VX-509 treatment resulted in dose-dependent reduction in ankle swelling and paw weight and improved paw histopathology scores in the rat collagen-induced arthritis (CIA) model. In a mouse model of oxazolone-induced delayed-type hypersensitivity (DTH), VX-509 reduced the T-cell-mediated inflammatory response in skin. For the detailed information of decernotinib (VX-509,adelatinib), the solubility of decernotinib (VX-509,adelatinib) in water, the solubility of decernotinib (VX-509,adelatinib) in DMSO, the solubility of decernotinib (VX-509,adelatinib) in PBS buffer, the animal experiment (test) of decernotinib (VX-509,adelatinib), the cell expriment (test) of decernotinib (VX-509,adelatinib), the in vivo, in vitro and clinical trial test of decernotinib (VX-509,adelatinib), the EC50, IC50,and affinity,of decernotinib (VX-509,adelatinib), For the detailed information of decernotinib (VX-509,adelatinib), the solubility of decernotinib (VX-509,adelatinib) in water, the solubility of decernotinib (VX-509,adelatinib) in DMSO, the solubility of decernotinib (VX-509,adelatinib) in PBS buffer, the animal experiment (test) of decernotinib (VX-509,adelatinib), the cell expriment (test) of decernotinib (VX-509,adelatinib), the in vivo, in vitro and clinical trial test of decernotinib (VX-509,adelatinib), the EC50, IC50,and affinity,of decernotinib (VX-509,adelatinib), Please contact DC Chemicals. |
